http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9934789-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbfccf1372c3462353ecc8b4e146ac3a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93128ae21cb6e625a69403d6d42fe588 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
filingDate | 1999-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f713306c09ec16f80fba6db6d7c0a894 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0d43f1c2f7b3b6d2af6da29cf1f85bc |
publicationDate | 1999-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-9934789-A1 |
titleOfInvention | Use of serine protease inhibitors to inhibit pathophysiology and neuropathology in a host |
abstract | Methods are provided for inhibiting cell adhesion molecule cleavage in brain tissue of a host. In the subject methods, an effective amount of a protease inhibitor, particularly serine protease inhibitors, such as those that inhibit tPA and related proteases, is administered to the host. The subject methods find use in the treatment and prevention of pathophysiology and neuropathology in a host, such as the treatment of a variety of pathological conditions resulting from pathophysiology and/or excitotoxicity. Specific pathological conditions in which the subject methods find use include epilepsy (and related seizure states) and neuronal damage associated with excessive glutamate activity, e.g. resulting from an acute event such as hypoxia, head trauma or stroke. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0154729-A1 |
priorityDate | 1998-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 165.